MetLife stock has climbed approximately 42% from its 52-week low of $67.33 and recently tested all-time highs near $98. The question now circulating among retail and institutional investors alike is whether the rally has enough fuel to carry shares past the round-number $100 barrier and onward to $110 — a level that sits above every current Wall Street consensus target. Independent research platform 24/7 Wall St. has published a 12-month price target of $110.82 for MET, citing favorable risk-reward dynamics at current valuations. That target implies a gain of roughly 14% from recent trading levels, making it an ambitious but mathematically plausible objective within a reasonable timeframe.
MetLife, Inc. is one of the largest life insurers in the United States by assets, with a market capitalization of approximately $61.85 billion. The company operates across six segments: Group Benefits, Retirement and Income Solutions (RIS), Asia, Latin America, Europe/Middle East/Africa (EMEA), and MetLife Holdings. Its group benefits franchise holds a leading market position in the U.S., while international operations — particularly in Latin America and Asia — contribute meaningfully to diversified earnings. The company's recent acquisition of PineBridge Investments also signals a strategic push to grow its asset management business toward $1 trillion in assets under management (AUM).
The strongest catalyst behind any move toward $110 is MetLife's "New Frontier" five-year strategic plan (2024–2029). The initiative raises the bar substantially: management is targeting double-digit adjusted EPS compound annual growth, a 15%–17% adjusted ROE, and cumulative holding-company free cash flow exceeding $25 billion. In Q1 2026, the company already delivered a 17% ROE — the top end of its target range — alongside adjusted EPS of $2.42, which beat consensus estimates by more than 6%.
Capital returns provide another tailwind. MetLife raised its quarterly dividend by 4.4% to $0.5925 per share and repurchased roughly $750 million in stock during Q1 2026 alone, with an additional $200 million bought back in April. With approximately $1.1 billion remaining on the current buyback authorization and holding-company cash of $3.9 billion, the company has ample capacity to continue supporting its share price through disciplined capital deployment.
The macroeconomic backdrop also favors large life insurers. Elevated interest rates have boosted bond portfolio yields across the sector. MetLife reported pretax variable investment income of $518 million in Q1 2026, reflecting strong returns from its private equity and venture capital holdings. Persistent higher-for-longer rate expectations would continue to support net investment income, a critical earnings driver for any life insurance company.
Wall Street's posture on MetLife has turned increasingly constructive. Following the Q1 2026 earnings beat, TD Cowen lifted its price target from $87 to $105, JPMorgan raised its target from $96 to $106, and KBW moved from $98 to $105. UBS and Mizuho also raised targets to $105 and $102, respectively. The overall analyst consensus stands at "Moderate Buy," with an average 12-month price target near $100.50 according to MarketBeat data. While no major Wall Street firm currently publishes a target as high as $110, the trajectory of recent revisions — consistently higher across multiple firms — suggests that additional upward adjustments are possible if execution under the New Frontier plan continues at its current pace.
Several risks could stall MetLife's momentum well before shares approach $110. In March 2026, the stock was removed from the S&P 100 index, triggering forced selling by passive funds and exchange-traded funds (ETFs) that track the benchmark. Although the stock recovered and reached new highs by July, the episode highlights the structural vulnerability that index-driven flows can create for large-cap financial stocks.
MetLife also carries a debt-to-equity ratio of approximately 0.53, which, while manageable for a large insurer, sits above some peers. The company reported net investment losses from trading activity in Q1 2026, and its GAAP net income of $1.1 billion materially lagged adjusted earnings due to these mark-to-market effects. Additionally, forward P/E ratios have expanded — the trailing P/E of around 18.6 is above MetLife's five-year median near 14 — meaning the stock is no longer the deep-value opportunity it was a year ago. Any earnings disappointment, interest rate pivot, or insurance underwriting shock could reset expectations quickly.
From a technical perspective, MET faces a clearly defined path of resistance. The $97.80 level represents the 52-week high and the all-time high zone — a decisive breakout above that mark would likely be the first prerequisite for any sustained advance. Beyond that, $100 stands as a psychological round-number barrier that tends to attract selling pressure on initial approaches. The 50-day moving average near $88–$89 and the 200-day moving average near $80 serve as major support zones that have contained pullbacks throughout 2026. A break below the 200-day moving average would seriously undermine the bullish thesis and likely delay any journey toward $110 indefinitely.
Traders seeking a data-driven edge in timing their entries and exits can turn to Tickeron's AI Daily Buy/Sell Signals. This tool uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating actionable Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI-powered analysis. Rather than manually sifting through charts and news flow, traders can use these signals to surface new opportunities, monitor existing positions for changing trends, and respond more efficiently to shifts in market sentiment. For investors tracking whether MET can sustain its climb toward higher price targets, AI-driven tools can help filter the noise and highlight meaningful inflection points as they develop.
The $110 target for MetLife stock is ambitious — it sits roughly 10% above the most bullish Wall Street price targets currently published — but it is not unrealistic given the company's accelerating execution under the New Frontier plan. The combination of double-digit EPS growth targets, aggressive share buybacks, a rising dividend, and a favorable interest rate environment provides a credible fundamental foundation. However, the path from $96 to $110 requires several conditions to align: continued earnings beats, a decisive break and hold above the $100 psychological level, stable or rising interest rates, and no major deterioration in credit markets or global economic conditions. Investors should monitor the upcoming Q2 2026 earnings report in early August and watch whether analyst price targets continue their upward drift — both would offer important signals about the viability of the $110 scenario.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MET has been closely correlated with PRU. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if MET jumps, then PRU could also see price increases.